Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com -- Sanofi (NASDAQ:SNY), the French healthcare group, revealed on Thursday that it has entered into an agreement to acquire DR-0201, an autoimmune disease treatment from biopharmaceutical company Dren Bio.
The acquisition will be conducted through Dren Bio’s affiliate, Dren-0201.
The deal involves an upfront payment of $600 million by Sanofi. In addition to this initial payment, the agreement also includes potential future payments which could total up to $1.3 billion.
Sanofi disclosed that the transaction is slated to be finalized in the second quarter of 2025. The acquisition of DR-0201 is part of Sanofi’s ongoing efforts to enhance its portfolio in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.